Journal of Clinical and Aesthetic Dermatology

MauiDerm 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link:

Contents of this Issue


Page 9 of 31

JCAD S10 journal of clinical and aesthetic dermatology JCAD journal of clinical and aesthetic dermatology May 2017 • Volume 10 • Number 5 (Supplement 1) t obacco use and food allergy. A dditional analyses were performed in subpopulations with ≥3 years of follow- up. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI); metabolic disorders were a covariate in the entire population analyses. R esults: A total of 132,461 AD patients were matched to 397,383 controls; 62.9 percent female, mean age 47.2 years. Exclusion of patients with a history of events resulted in evaluable CV disease cohorts of 119,580 AD patients and 368,580 controls, and MACE cohorts of 132,460 AD patients and 397,380 controls. The post-index incidence of CV disease was 8.4 percent in the AD cohort and 6.3 percent in controls; OR of 1.10 (95% CI 1.08-1.13) indicated AD patients were 1.10 times more likely to develop CV disease than controls. For MACE, the post-index incidence was 2.6 percent and 1.9 percent in AD and control cohorts, respectively; AD patients had a 1.14 (95% CI 1.09-1.19) greater likelihood of MACE. AD patients with metabolic disorders had a 1.09 (95% CI 1.07–1.12) and 1.13 (95% CI 1.09–1.18) times greater likelihood for developing CV disease and MACE, respectively, than non-AD controls; among AD patients without metabolic disorders, ORs were 1.25 (95% CI 1.13–1.39) for CV disease and 1.22 (95% CI 1.01–1.47) for MACE. Among patients with ≥3 years follow-up, ORs were 1.33 (95% CI 1.28-1.38) and 1.30 (95% CI 1.23-1.39) for CV disease and MACE, respectively, for AD patients with metabolic disorders, and 1.41 (95% CI 1.15–1.71) and 1.46 (95% CI 1.01–2.10) for CV disease and MACE, respectively, for AD patients without metabolic disorders. Conclusion: Adults with AD appear to be at greater risk of CV disease and MACE compared with matched c ontrols without AD even when a ccounting for the presence of variables that may contribute to CV risk (i.e., metabolic disorders). The Efficacy and Safety of Desoximethasone 0.25% Spray in Adult Atopic Dermatitis Subjects— A Pilot Study Presenters: Lauren K. Hoffman,BS, 1 Leon Kircik, MD 2 Affiliations: 1 Albert Einstein College of Medicine, Bronx NY; 2 Mount Sinai Medical Center, New York, NY; Physicians Skin Care, PLLC, Louisville, KY Background: Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disorder. One of the most disturbing symptoms of AD is pruritus. The first-line treatment for AD is topical corticosteroids, and other treatments include topical immunomodulators, oral antihistamines, and antidepressants. Desoximethasone 0.25% spray is a super-potent topical corticosteroid delivered in a novel way and it may be a suitable option for the treatment of pruritus in adult atopic dermatitis patients. Study Design: A single-center, open labeled, pilot study was conducted to investigate the efficacy and safety of desoximethasone 0.25% spray in alleviating the pruritus of adult atopic dermatitis patients. Results: Twice-daily application of desoximethasone 0.25% spray to affected areas resulted in a significant reduction in all outcomes (IGA, pruritus severity, and VAS assessment of pruritus) within one week of initiation of treatment. The reductions exhibited were sustained throughout the study period of four weeks. Upon completion of the study, all subjects were rated as "Clear" or "Almost Clear" o n the IGA. Nine subjects (60%) rated p ruritus as "None" on the pruritus severity scale and average VAS scores significantly decreased from baseline (75, ±6) to Week 4 (7, ±9). Significant improvements in the quality of life as measured by the DLQI were observed, with an average score of 2 (±5) at Week 4 . No adverse events were reported. Conclusion: Desoximethasone 0.25% spray is effective for treating pruritic symptoms of AD. Given its efficacy and convenience as a spray, desoximethasone 0.25% spray should continue to be evaluated as a treatment for AD. HYPERHIDROSIS DRM04 For the Treatment of Primary Axillary Hyperhidrosis: Primary Results from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials Presenters: David M. Pariser, 1 Adelaide A. Hebert, 2 Alexander Nast, 3 William P. Werschler, 4 Stephen J. Shideler, 5 Lawrence Green, 6 Hans Hofland, 7 Janice Drew, 7 Janet Quiring, 8 Dee Anna Glaser 9 Affiliations: 1 Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA; 2 University of Texas Health Science Center, Houston, TX; 3 Charité– Universitätsmedizin Berlin, Berlin, Germany; 4 Premier Clinical Research, Spokane, WA; 5 Shideler Dermatology and Skin Care Center, Carmel, IN; 6 George Washington University School of Medicine, Washington, DC; 7 Dermira, Inc., Menlo Park, CA; 8 QST Consultations, Allendale, MI; 9 Saint Louis University, St. Louis, MO Background: Approximately 2.8 percent of the US population (7.8 million) suffer from hyperhidrosis. Treatment options for patients (pts) are

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - MauiDerm 2017